Premium
Novel approaches to the treatment of hyperglycaemia in type 2 diabetes mellitus
Author(s) -
Galligan A.,
Greenaway T. M.
Publication year - 2016
Publication title -
internal medicine journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.596
H-Index - 70
eISSN - 1445-5994
pISSN - 1444-0903
DOI - 10.1111/imj.13070
Subject(s) - medicine , type 2 diabetes , diabetes mellitus , intensive care medicine , type 2 diabetes mellitus , insulin , risk factor , adverse effect , endocrinology
Control of hyperglycaemia is a fundamental therapeutic goal in patients with type 2 diabetes. The progressive nature of β‐cell dysfunction in type 2 diabetes leads to the need for escalating anti‐hyperglycaemic treatment, including insulin, in most patients. Given the prevalence of complications such as weight gain and hypoglycaemia associated with traditional anti‐hyperglycaemic agents ( AHA ), including sulphonylureas and insulin, it is unsurprising that recent years have seen the development of novel agents to treat hyperglycaemia. With increasing evidence supporting the need for a multi‐faceted approach to the prevention of adverse cardiovascular events in people with type 2 diabetes, a patient‐centred and individualised management strategy addressing lifestyle, cardiovascular risk factor modification and glycaemic control remains critical in improving outcomes in these patients.